Metformin's Expanding Reach: From Blood Sugar Control to Fighting Aging

Metformin has been the cornerstone of type 2 diabetes treatment since 1957, but a growing body of evidence suggests its therapeutic reach extends far beyond glycemic control. This comprehensive 2025 review, authored by researchers at the University of Pavia and the University of Toronto, synthesizes preclinical and clinical data on metformin's pleiotropic effects across a spectrum of age-related diseases, offering a detailed mechanistic framework for its broader applications.

At its core, metformin works by inhibiting mitochondrial respiratory chain complex I, which depletes ATP and raises intracellular AMP levels, thereby activating AMP-activated protein kinase (AMPK). This central hub regulates glucose and lipid metabolism, suppresses mTORC1 signaling, and promotes autophagy. In the liver, metformin reduces gluconeogenesis and glycogenolysis through both AMPK-dependent and independent pathways—including direct binding to the enzyme fructose-1,6-bisphosphatase-1. In skeletal muscle, it enhances GLUT-4 translocation and peripheral glucose uptake. In the gut, it modifies the microbiome, increasing beneficial bacteria like Akkermansia muciniphila and boosting short-chain fatty acid production and GLP-1 secretion.

The review's most forward-looking sections examine metformin's impact on hallmarks of aging. The drug activates the SIRT3-AMPK pathway, upregulates PGC-1α to promote mitochondrial biogenesis, inhibits the senescence-associated secretory phenotype (SASP), reduces telomere shortening, and maintains proteostasis by enhancing autophagy and reducing protein misfolding. These actions converge on biological aging processes in ways that have attracted serious clinical interest. In neurodegenerative disease, metformin shows evidence of reducing amyloid-beta aggregation and tau hyperphosphorylation in Alzheimer's models, and of protecting dopaminergic neurons via Nrf2 pathway activation in Parkinson's contexts. For cardiovascular disease, its anti-inflammatory and antioxidant effects appear cardioprotective beyond glucose lowering. In osteoporosis and age-related macular degeneration, AMPK-mediated pathways similarly suggest protective roles.

The most significant clinical development highlighted is the TAME (Targeting Aging with Metformin) trial—a 6-year, double-blind, placebo-controlled multicenter study enrolling approximately 3,000 non-diabetic adults aged 65–80 at high risk of age-related diseases. Participants receive 1,500 mg/day of metformin. This trial is designed to determine whether metformin can delay the composite onset of multiple age-related conditions, representing a landmark shift in how researchers conceptualize a small-molecule drug as a genuine geroprotective agent.

The authors acknowledge important caveats: much of the evidence for non-diabetic applications remains preclinical or derived from observational studies in diabetic populations, making it difficult to disentangle metformin's direct anti-aging effects from its glucose-lowering actions. Dosing, long-term tolerability in non-diabetic elderly populations, drug interactions, and renal function considerations all warrant careful attention. The TAME trial's results will be critical for translating these promising mechanistic findings into evidence-based clinical recommendations.